课题基金 / 基金详情

Task V02: Manufacture of Influenza for Human Challenge Clinical Trials

Task V02: Manufacture of Influenza for Human Challenge Clinical Trials
任务V02:制造用于人类挑战临床试验的流感病毒
批准号:
10269863
负责人:
THOMAS HASSELL
金额:
$9.67万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-05-15 至 2028-05-14

项目摘要

项目成果

THOMAS HASSELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against a wide array of infectious diseases. This contract also provides for manufacture of candidate vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nanoparticle-based development for HIV-1 biomolecule delivery
NIAID Process Development and Analytical Support for Development of HIV Vaccines
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine
Nanoparticle-based development for HIV-1 biomolecule delivery
海外基金